Entyvio Associated With Lowest Risk of Adverse Events in Patients with UC, Study Finds
October 2nd 2024Treatment with Entyvio (vedolizumab), an integrin receptor antagonist, followed by Humira (adalimumab), a tumor necrosis factor blocker, resulted in the lowest overall incidence of adverse events, according to an industry-sponsored study.
Read More
The ACA Got Some Airtime in Last Night's VP Debate
October 2nd 2024Sen. J.D. Vance credited Donald Trump with "salvaging" the Affordable Care Act (ACA). Gov. Tim Walz said Trump worked to repeal the ACA and Vance has proposals that would bring back pre-ACA limitations on health insurance for people with preexisting conditions.
Read More
Medicare Advantage and Medicare: Not Too Much Rocking of the Boat by Either Candidate or Party
September 26th 2024Neither party wants to be perceived as threatening the overall Medicare program. The Biden administration did take steps to reduce payment to Medicare Advantage plans. Insurance companies objected, but some industry observers said it was an overdue correction.
Read More
FDA Accepts sNDA for Foam Psoriasis Drug Zoryve
September 24th 2024The FDA has already approved Zoryve cream (0.3% and 0.15%) for plaque psoriasis and atopic dermatitis in adults and children ages 6 and up. Currently, Zoryve foam 0.3% is only approved to treat seborrheic dermatitis in adult and pediatric patients 9 years and older.
Read More
FDA Expands Bimzelx Approval to Three Additional Autoimmune Indications
September 23rd 2024Bimzelx was first approved last year for the treatment of moderate to severe psoriasis in adults, making it the first and only IL-17A and IL-17F inhibitor approved in the United States for four autoimmune diseases.
Read More
FTC Sues PBMs for Artificially Hiking Insulin Prices
September 20th 2024A news release about the complaint says the "big 3 " pharmacy benefit managers — CVS Caremark, Optum Rx and Express Scripts — have kept hundreds of millions of dollars of rebates while excluding insulin products with lower list prices from their formularies.
Read More